The clinical pharmacology of loop diuretics in the pediatric patient

Pediatric Nephrology

Volumn 12, Issue 7, 1998, Pages 603-616

  Eades, Shannan K ^a   Christensen, Michael L ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Bumetanide; Furosemide; Loop diuretics; Tolerance

Indexed keywords

BUMETANIDE; FUROSEMIDE; LOOP DIURETIC AGENT;

CLINICAL PHARMACOLOGY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HENLE LOOP; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SODIUM ABSORPTION;

BUMETANIDE; CHILD; DIURETICS; DRUG RESISTANCE; DRUG TOLERANCE; FUROSEMIDE; HUMANS; KIDNEY DISEASES; LOOP OF HENLE;

EID: 0031678676     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670050514     Document Type: Review

References (131)

1. Witte MK, Stork JE, Blumer JL (1986) Diuretic therapeutics in the pediatric patient. Am J Cardiol 57:44A-53A
2. Andreasen F, Lauridsen IN, Hansen FA, Christensen S, Steiness E (1989) Dose dependency of furosemide-induced sodium excretion. J Pharmacol Exp Ther 248:1182-1188
3. Branch RA, Roberts CJC, Homeida M, Levine D (1977) Determinants of response to frusemide in normal subjects. Br J Clin Pharmacol 4:121-127
4. Johnston UD, Nicholls DP, Kondowe GB, Finch MB (1986) Comparison of the acute vascular effects of frusemide and bumetanide. Br J Clin Pharmacol 21:359-364
5. Kaojarern S, Day B, Brater C (1982) The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 22:69-74
6. Kron BG, Sjöström PA, Karlberg BE, Odlind BG (1994) Acute tolerance to furosemide. Pretreatment with captopril or prazosin does not influence diuresis and natriuresis. Scand J Urol Nephrol 28:337-344
7. Okaniwa T, Echizen H, Ishizaki T, Kasao M, Iizuka T (1990) Pharmacodynamic characterization of posture-related diuretic and saluretic responses to furosemide in humans. J Pharmacol Exp Ther 255:716-723
8. Passmore AP, Whitehead EM, Johnston GD (1989) Comparison of the acute renal and peripheral vascular responses to frusemide and bumetanide at low and high dose. Br J Clin Pharmacol 27:305-312
9. Sjöström PA, Kron BG, Odlind BG (1993) Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration. Eur J Clin Pharmacol 45:135-139
10. Wakelkamp M, Alván G, Gabrielsson J, Paintaud G (1996) Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 60:75-88
11. Mirochnick MH, Miceli JJ, Chapron DJ, Kramer PA, Raye JR (1987) Furosemide pharmacodynamics following acute and chronic administration. Pediatr Res 21:239A
12. Mirochnik MH, Miceli JJ, Kramer PA, Chapron DJ, Raye JR (1988) Furosemide pharmacokinetics in very low birth weight infants. J Pediatr 112:653-657
13. Wells TG, Fasules JW, Taylor BJ, Kearns GL (1992) Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. J Pediatr 121:974-980
14. Brater DC (1994) Diuretic resistance: mechanisms and therapeutic strategies. Cardiology 84 [Suppl 2]:57-67
15. Chennavasin P, Seiwell R, Brater DC, Liang WMM (1979) Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 16:187-195
16. Odlind B (1983) Determinants of access of diuretics to their site of action. Fed Proc 42:1703-1706
17. Brater DC (1991) Clinical pharmacology of loop diuretics. Drugs 41 [Suppl 3]:14-22
18. Wittner M, Di Stefano A, Wangemann P, Greger R (1991) How do loop diuretics act? Drugs 41 [Suppl 3]:1-13
19. Lunau HE, Bak M, Petersen JS, Shalmi M, Marcussen N, Christensen S (1994) Renal adaptations to continuous administration of furosemide and bendroflumethiazide in rats. Pharmacol Toxicol 74:216-222
20. Giebisch G, Klein-Robberihaar G (1993) Recent studies on the characterization of loop diuretics. J Cardiovasc Pharmacol 22:S1-S10
21. Brater DC (1983) Pharmacodynamic considerations in the use of diuretics. Annu Rev Pharmacol Toxicol 23:45-62
22. Kirkendall WM, Stein JH (1968) Clinical pharmacology of furosemide and ethacrynic acid. Am J Cardiol 22:162-167
23. Birtch AG, Zakheim RM, Jones LG, Barger AC (1967) Redistribution of renal blood flow produced by furosemide and ethacrynic acid. Circ Res 21:869-878
24. Mackay IG, Muir AL, Watson ML (1984) Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man. Br J Clin Pharmacol 17:513-519
25. Friedman Z, Demers LM, Marks KH, Uhrmann S, Maisels MJ (1978) Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants. J Pediatr 93:512-515
26. Scherer B, Weber PC (1979) Time-dependent changes in prostaglandin excretion in response to furosemide in man. Clin Sci (Colch) 56:77-81
27. Rector FC Jr (1983) Sodium, bicarbonate, and chloride absorption by the proximal tubule. Am J Physiol 244:F461-F471
28. Dirks JH, Cirksena WJ, Berliner RW (1966) Micropuncture study of the effect of various diuretics on sodium reabsorption by the proximal tubules of the dog. J Clin Invest 45: 1875-1885
29. Knox FG, Wright FS, Howards SS, Berliner RW (1969) Effect of furosemide on sodium reabsorption by proximal tubule of the dog. Am J Physiol 217:192-198
30. Figueras J, Weil MH (1978) Blood volume prior to and following treatment of acute cardiogenic pulmonary edema. Circulation 57:349-355
31. Johnston GD, Nichols DP, Leahey WJ (1984) The dose response characteristics of the acute non diuretic peripheral vascular effects of frusemide in normal subjects. Br J Clin Pharmacol 18:75-81
32. O'Donovan BH, Bell EF (1989) Effects of furosemide on body water compartments in infants with bronchopulmonary dysplasia. Pediatr Res 26:121-124
33. Schuster C, Weil MH, Besso J, Carpio M, Henning RJ (1984) Blood volume following diuresis induced by furosemide. Am J Med 76:585-592
34. Segar JL, Chemtob S, Bell EF (1997) Changes in body water compartments with diuretic therapy in infants with chronic lung disease. Early Hum Dev 48:99-107
35. Yetman AT, Singh NC, Parbtani A, Loft JA, Linley MA, Johnson CC, Morgan D (1996) Acute hemodynamic and neurohormonal effects of furosemide in critically ill pediatric patients. Crit Care Med 24:398-402
36. Johnston GD, Nichols DP, Leahey WJ, Finch MB (1983) The effects of captopril on the acute vascular responses of frusemide in man. Clin Sci (Colch) 65:359-363
37. Green TP, Thompson TR, Johnson DE, Lock JE (1983) Diuresis and pulmonary function in premature infants with respiratory distress syndrome. J Pediatr 103:618-623
38. Green TP, Johnson DE, Bass JL, Landrum BG, Ferrara TB, Thompson TR (1988) Prophylactic furosemide in severe respiratory distress syndrome: blinded prospective study. J Pediatr 112:605-612
39. Kugelman A, Durand M, Garg M (1997) Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. Pediatrics 99:71-75
40. Ohki Y, Nako Y, Koizumi T, Morikawa A (1997) The effect of aerosolized furosemide in infants with chronic lung disease. Acta Paediatr 86:656-660
41. Prabhu VG, Keszler M, Dhanireddy R (1997) Pulmonary function changes after nebulised and intravenous frusemide in ventilated premature infants. Arch Dis Child 77:F32-F35
42. Stevens EL, Uyehara FT, Southgate WM, Nakamura KT (1992) Furosemide differentially relaxes airway and vascular smooth muscle in fetal, newborn, and adult guinea pigs. Am Rev Respir Dis 146:1192-1197
43. Bianco S, Vaghi A, Robuschi M, Pasargiklian M (1988) Prevention of exercise-induced bronchoconstriction by inhaled furosemide. Lancet 11:252-255
44. Bianco S, Pieroni MG, Refini RM, Rattori L, Sestini P (1989) Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med 321:1069-1073
45. Redrup AC, Pearce FL (1994) Effect of loop diuretics on rat peritoneal and human lung mast cells. Agents Actions 41: C47-C48
46. Ravel NC, Leef KH, Antunes MJ, Stefano JL (1994) Effect of aerosolized furosemide on pulmonary function in infants with BPD: a randomized, blinded placebo controlled trial. Pediatr Res 35:350A
47. Prabhu VG (1997) Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia (letter). Pediatrics 100:420
48. Aufricht C, Votava F, Marx M, Frenzel K, Simbruner G (1997) Intratracheal furosemide in infants after cardiac surgery: its effects on lung mechanics and urinary output, and its levels in plasma and tracheal aspirate. Intensive Care Med 23:992-997
49. Duarte CG (1968) Effects of ethacrynic acid and furosemide on urinary calcium, phosphate and magnesium. Metabolism 17:867-876
50. Quamme GA (1981) Effect of furosemide on calcium and magnesium transport in the rat nephron. Am J Physiol 241: F340-F347
51. Reyes AJ (1993) Renal excretory profiles of loop diuretics: consequences for therapeutic application. J Cardiovasc Pharmacol 22 [Suppl 3]:S11-S23
52. Wittner M, Mandon B, Roinel N, Rouffignac C de, Di Stefano A (1993) Hormonal stimulation of Ca2+ and Mg2+ transport in the cortical thick ascending limb of Henle's loop of the mouse: evidence for a change in the paracellular pathway permeability. Eur J Physiol 423:387-396
53. Gabow PA, Hanson TJ, Popovtzer MM, Schrier RW (1977) Furosemide-induced reduction in ionized calcium in hypoparathyroid patients. Ann Intern Med 86:579-581
54. Shareghi GR, Agus ZS (1982) Magnesium transport in the cortical thick ascending limb of Henle's loop of the rabbit. J Clin Invest 69:759-769
55. Jacinto JS, Modanlou HD, Grade M, Strauss AA, Bosu SK (1988) Renal calcifications. Incidence in very low birth weight infants. Pediatrics 81:31-35
56. Hufnagle KG, Khan SN, Penn D, Cacciarelli A, Williams P (1982) Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 70:360-363
57. Rowe JC, Carey DE, Goetz CA, Adams ND, Horak E (1989) Effect of high calcium and phosphorus intake on mineral retention in very low birth weight infants chronically treated with furosemide. J Pediatr Gastroenterol Nutr 9:206-211
58. Atkinson SA, Shah JK, McGee C, Steele BT (1988) Mineral excretion in premature infants receiving various diuretic therapies. J Pediatr 113:540-545
59. Campfield T, Braden G, Flynn-Valone P, Powell S (1997) Effect of diuretics on urinary oxalate, calcium, and sodium excretion in very low birth weight infants. Pediatrics 99: 814-818
60. Benaron DA, Yorgin PD, Lapuk S, Gibson R, Dennery PA (1992) Alkalemia in a newborn infant. J Pediatr 120: 489-494
61. Eiam-Ong S, Kurtzman NA, Sabatini S (1993) Effect of furosemide-induced hypokalemic metabolic alkalosis on renal transport enzymes. Kidney Int 43:1015-1020
62. Laudignon N, Ciampi A, Coupal L, Chemtob S, Aranda JV (1989) Furosemide and ethacrynic acid: risk factors for the occurrence of serum electrolyte abnormalities and metabolic alkalosis in newborns and infants. Acta Paediatr Scand 78: 133-135
63. Singh SE, Murphy JF, Gray OP (1984) Metabolic alkalosis in a neonate after frusemide. Arch Dis Child 59:907
64. Downing GJ, Egelhoff JC, Daily DK, Thomas MK, Alon U (1992) Kidney function in very low birth weight infants with furosemide-related renal calcifications at ages 1 to 2 years. J Pediatr 120:599-604
65. Cohanim M, Yendt ER (1980) Reduction of urine oxalate during long-term thiazide therapy in patients with calcium urolithiasis. Invest Urol 18:170-173
66. Constanze LS, Weiner IM (1984) On the hypercalciuric action of chlorothiazide. J Clin Invest 54:628
67. Lloyd-Mostyn RH, Lord IJ (1971) Ototoxicity of intravenous frusemide Lancet II:1156
68. Vargish T, Benjamin R, Shenkman L (1970) Deafness from furosemide. Ann Intern Med 72:761
69. Venkateswaran PS (1971) Transient deafness from high doses of frusemide. B M J 4:113-114
70. Wigand ME, Heidland A (1971) Ototoxic side-effects of high doses of frusemide in patients with uraemia. Postgrad Med J 47 [Suppl]:54-56
71. Borradori C, Fawer CL, Buclin T, Calame A (1997) Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate 71:1-10
72. Rybak LP (1985) Furosemide ototoxicity: clinical and experimental aspects. Laryngoscope 95 [Suppl 38]:1-14
73. Brummett RE, Bendrick T, Himes D (1981) Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin. J Clin Pharmacol 21:628-636
74. Kaka JS, Lyman C, Kilarski DJ (1984) Tobramycin-furosemide interaction. Drug Intell Clin Pharm 18:235-238
75. Rybak LP (1982) Pathophysiology of furosemide ototoxicity. J Otolaryngol 11:127-133
76. Green TP, Thompson TR, Johnson DE, Lock JE (1981) Furosemide use in premature infants and appearance of patent ductus arteriosus. Am J Dis Child 135:239-243
77. Green TP, Thompson TR, Johnson DE, Lock JE (1983) Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med 308: 743-748
78. Romagnoli C, Zecca E, Papacci P, De Carolis MP, Giannini R, Gallini F, Tortorolo G (1997) Furosemide does not prevent indomethacin-induced renal side effects in preterm infants. Clin Pharmacol Ther 62:181-186
79. Yeh TF, Wilks A, Singh J, Betkerur M, Lilien L, Pildes RS (1982) Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arte-riosus. J Pediatr 101:433-437
80. Yeh TF, Wilks A, Luken J, Pildes RS (1986) Indomethacin therapy in premature infants with patent ductus arteriosus and oliguria. Dev Pharmacol Ther 9:369-374
81. Sjöström PA, Kron BG, Odlind BG (1995) Determinants of furosemide delivery to its site of action. Clin Nephrol 43: S38-S41
82. Branch RA (1983) Role of binding in distribution of furosemide: where is nonrenal clearance? Fed Proc 42:1699-1702
83. Boles Ponto LL, Schoenwald RD (1990) Furosemide - a pharmacokinetic/pharmacodynamic review. Clin Pharmacokinet 18:381-408
84. Brater DC (1986) Disposition and response to bumetanide and furosemide. Am J Cardiol 57:20A-25A
85. Tuck S, Morselli P, Broquaire M, Vert P (1983) Plasma and urinary kinetics of furosemide in newborn infants. J Pediatr 103:481-485
86. Aranda JV, Perez J, Sitar DS, Collinge J, Portuguez-Malavasi A, Duffy B, Dupont C (1978) Pharmacokinetic disposition and protein binding of furosemide in newborn infants. J Pediatr 93:507-511
87. Aranda JV, Lambert C, Perez J, Turmen T, Sitar DS (1982) Metabolism and renal elimination of furosemide in the newborn infant. J Pediatr 101:777-781
88. Lopez AM, Modi MW, Adams JA, Horner GP, De Grazia FT, Goldberg RN (1990) Pharmacokinetics of bumetanide in the newborn infant (abstract). Pediatr Res 27:62A
89. Peterson RG, Simmons MA, Rumack BH, Levine RL, Brooks JG (1980) Pharmacology of furosemide in the premature newborn infant. Pediatr Pharmacol Ther 97:139-143
90. Shankaran S, Ilagan N, Liang K-C, Bhavsar V, Kauffman R (1989) Bumetanide pharmacokinetics in preterm neonates (abstract). Pediatr Res 25:72A
91. Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL (1996) Pharmacokinetics of bumetanide in critically ill infants. Clin Pharmacol Ther 60:405-413
92. Vert P, Broquaire M, Legagneur M, Morselli PL (1982) Pharmacokinetics of furosemide in neonates. Eur J Clin Pharmacol 22:39-45
93. Hammarlund-Udenaes M, Benet LZ (1989) Furosemide pharmacokinetics and pharmacodynamics in health and disease - an update. J Pharmacokinet Biopharm 17:1-46
94. Eades SK, Quasney MW, Ring JC, Wilson MB, Mottern RK, Christensen ML (1998) Pharmacokinetics of continuous infusion furosemide in critically ill children (abstract). J Invest Med 46:31A
95. Verbeeck RK, Gerkens JF, Wilkinion GR, Branch RA (1981) Disposition of furosemide in functionally hepatectomized dogs. J Pharmacol Exp Ther 216:479-483
96. Verbeec RK, Patwardhan RV, Villeneuve J, Wilkinson GR, Branch RA (1982) Furosemide disposition in cirrhosis. Clin Pharmacol Ther 31:719-725
97. Rakhit A, Kochak GM, Tipnis V, Hurley ME (1987) Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 41:580-586
98. Marcantonio LA, Auld WHR, Skellern GG, Howes CA, Murdoch WR, Purohit R (1982) The pharmacokinetics and pharmacodynamics of bumetanide in normal subjects. J Pharmacokinet Biopharm 10:393-409
99. Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL (1996) Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants. Clin Pharmacol Ther 60:414-423
100. Walker PC, Berry NS, Edwards DJ (1989) Protein binding characteristics of bumetanide. Dev Pharmacol Ther 12: 13-18
101. Green TP (1988) Diuretic pharmacokinetics and pharmacodynamics in infants from the analysis of urinary drug excretion data. Dev Pharmacol Ther 11:357-365
102. Sullivan JE, Witte MK, Yamashita TS, Myers CM, Blumer JL (1996) Dose-ranging evaluation of bumetanide pharmacodynamics in critically ill infants. Clin Pharmacol Ther 60: 424-434
103. Brater DC, Chennavasin P, Seiwell R (1980) Furosemide in patients with heart failure. Shift of the dose-response relationship. Clin Pharmacol Ther 28:182-186
104. Brater DC (1985) Resistance to loop diuretics. Why it happens and what to do about it. Drugs 30:427-443
105. Brater DC (1994) Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J 72:S40-S43
106. Olden RW van, Meyel JJM van, Gerlag PGG (1995) Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. Eur J Clin Pharmacol 47: 483-488
107. Voelker JR, Brown-Cartwright D, Anderson S, Leinfelder J, Sica DA, Kokko JP, Brater DC (1987) Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 32:572-578
108. Brater DC, Anderson SA, Brown-Cartwright D (1986) Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin Pharmacol Ther 40:134-139
109. Copeland JG, Campbell DW, Plachetka JR, Salomon NW, Larson DF (1983) Diuresis with continuous infusion of furosemide after cardiac surgery. Am J Surg 146:796-799
110. Dettorre MD, Stidham GL, Watson DC, Ring JC (1994) Enhanced diuresis with continuous furosemide infusion in postoperative pediatric cardiac surgery patients (abstract). Crit Care Med 22:A183
111. Dormans TPJ, Meyel JJM van, Gerlag PGG, Tan Y, Russel FGM, Smits P (1996) Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 28:376-382
112. Lahav M, Regev A, Ra'anani P, Theodor E (1992) Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 102:725-731
113. Rudy DW, Voelker JR, Greene PK, Esparza FA, Brater DC (1991) Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 115:360-366
114. Singh NC, Kissoon N, Mofada SA, Bennett M, Bohn DJ (1992) Comparison of continuous versus intermittent furosemide administration in postoperative pediatric cardiac patients. Crit Care Med 20:17-21
115. Meyel JJ van, Smits P, Russel FGM, Gerlag PGG, Gribnau FWJ (1992) Diuretic efficiency of furosemide during continuous administration versus bolus injection in healthy volunteers. Clin Pharmacol Ther 51:440-444
116. Luciani GB, Nichani S, Chang AC, Wells WJ, Newth CJ, Starnes VA (1997) Continuous versus intermittent furosemide infusion in critically ill infants after open heart operations. Ann Thorac Surg 64:1133-1139
117. Brater DC (1983) Determinants of the overall response to furosemide: pharmacokinetics and pharmacodynamics. Fed Proc 42:1711-1713
118. Davison AM, Lambie AT, Verth AH, Cash JD (1974) Saltpoor human albumin in management of nephrotic syndrome. BMJ 1:481-484
119. Haws RM, Baum M (1993) Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics 91:1142-1146
120. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y (1987) Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 32:198-203
121. Mattana J, Patel A, Ilunga C, Singhal PC (1996) Furosemide-albumin complexes in refractory nephrotic syndrome and chronic renal failure. Nephron 73:122-123
122. Sandroni S (1988) Refractory edema: evolving status of albumin and furosemide. J Fla Med Assoc 75:676-677
123. Weiss RA, Schoeneman M, Greifer I (1984) Treatment of severe nephrotic edema with albumin and furosemide. N Y State J Med 84:384-386
124. Kirchner KA, Voelker JR, Brater DC (1990) Intratubular albumin blunts the response to furosemide - a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 252:1097-1101
125. Kirchner KA, Voelker JR, Brater DC (1991) Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 40:418-424
126. Sica DA, Gehr TWB (1996) Diuretic combinations in refractory oedema states. Clin Pharmacokinet 30:229-249
127. Arnold WC (1984) Efficacy of metolazone and furosemide in children with furosemide-resistant edema. Pediatrics 74:872-875
128. Garin EH (1987) A comparison of combinations of diuretics in nephrotic edema. Am J Dis Child 141:769-771
129. Segar JL, Robillard JE, Johnson KJ, Bell EF, Chemtob S (1992) Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. J Pediatr 120:966-973
130. Cachero SD, Lofland G, Springate JE, Feld LG (1990) Combination of metolazone and furosemide in the treatment of edema in the first month of life. Child Nephrol Urol 10: 161-163
131. Chemtob S, Papageorgiou A, Souich P du, Aranda JV (1987) Cumulative increase in serum furosemide concentration following repeated doses in the newborn. Am J Perinatol 4:203-205